회사 개요
Aspire Biopharma Holdings, Inc. (ASBP) operates as an early-stage biopharmaceutical entity dedicated to developing and marketing disruptive technology focused on novel sublingual delivery mechanisms within the United States. The company specifically offers Instaprin, a sublingual aspirin product characterized as a soluble, pH neutral, and fast-acting formulation designed to address specific therapeutic delivery needs. This business operates within the broader Healthcare sector, specifically classified under the Biotechnology industry, which typically entails significant research and development expenditures prior to commercialization and regulatory approval. The company's financial scale is defined by a market capitalization of $6.03M and a trailing twelve-month revenue of $6,202, while specific employee count data is not available in current reports. These valuation and revenue figures indicate that ASBP remains in a pre-profitability stage where cash consumption is likely high, consistent with the profile of early-stage biotechnology firms that prioritize product development over immediate revenue generation.
재무 건전성
The company reported a trailing twelve-month revenue of $6,202 alongside a net income of -$24,480,848, revealing a substantial disparity that highlights an aggressive cost structure typical of pre-revenue or early-stage clinical development phases where operating expenses significantly outweigh income. Despite the negative net income, the company reports a free cash flow of $15.39M, which suggests a degree of financial flexibility potentially derived from asset sales, financing activities, or non-operating sources, though this figure contrasts sharply with the negative operating performance. The financial margins paint a complex picture, with a gross margin of -1.9% and a profit margin of 0.0%, while the operating margin stands at an extreme -43403.5%, indicating that operating expenses are vastly disproportionate to the revenue base. In terms of leverage, the company holds $1.00M in cash against $5.18M in debt, resulting in a debt-to-equity ratio that is not calculable due to the negative equity position implied by the price-to-book metric. The balance sheet appears highly leveraged relative to its cash reserves, as the debt load of $5.18M exceeds the liquid cash on hand by more than five times. Liquidity is constrained by a current ratio of 0.17, which indicates that current liabilities significantly exceed current assets, posing potential challenges for meeting short-term obligations without additional financing. Return on equity is not available due to the negative equity position, while return on assets stands at -446.9%, revealing that the asset base is generating negative returns relative to the capital employed.
밸류에이션 평가
The trailing twelve-month P/E ratio is not available due to the company's lack of earnings, and the forward P/E is also not available, implying that the market cannot value the stock based on expected earnings growth in the traditional sense. The price-to-book ratio is recorded at -0.66, a negative figure that indicates the market capitalization is less than the book value or that the equity value is negative, removing standard valuation comparisons based on book value multiples. The price-to-sales ratio is exceptionally high at 972.10, suggesting that the market is pricing the stock based on speculative future potential rather than current sales performance, while the EV/EBITDA multiple is not available. The stock has experienced extreme volatility over the past year, trading between a 52-week high of $35.00 and a 52-week low of $0.55. Given the wide range between these extremes, the current price trajectory is heavily dependent on recent market sentiment rather than fundamental value anchors. The beta value is 1.00, indicating that the stock's price volatility moves in tandem with the broader market index, offering no inherent hedge or amplified exposure compared to the general market.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both not available, preventing an analysis of whether earnings are growing faster or slower than revenue within a historical context. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that any generated cash or retained earnings are reinvested into the company's operations or research rather than distributed to shareholders. The absence of a dividend yield aligns with the company's status as an early-stage biopharmaceutical firm that must retain capital for development activities rather than rewarding income-seeking investors. Consequently, the overall growth and income profile is defined entirely by potential future product milestones and the ability to manage cash burn, rather than current profitability or income generation for shareholders.